Marlborough’s RXi Pharmaceuticals reported a steady year-over-year $2.2 million in losses as the clinical-stage therapeutics company continues to push forward on human trials of scarring treatments.
Research and development expenses for the quarter were $1.3 million, compared with $1.4 million for the same quarter in 2015. The company is currently pursuing human trials of a treatment for hypertrophic scars and an early-stage study of a treatment for retinal scarring.
As of the end of the quarter, the company had cash, cash equivalents and short-term investments of approximately $5.8 million, down from $10.6 million as of Dec. 31.
